Metabolic properties of IgG subclasses in man
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Metabolic properties of the four subclasses of human IgG were investigated by performing 47 turnover studies in individuals with normal IgG serum concentrations, as well as in patients with an increased level of one of the subclasses. Studies in 12 subjects with normal IgG serum concentration showed that the average biologic half-life of G(1), G(2), and G(4) was 21 days, while that of G(3) was only 7.1 days. Fractional catabolic rates of G(1), G(2), and G(4) were 6.9 to 8% of the intravascular pool per day. G(3), however, had a higher fractional catabolic rate, amounting to 16.8% of the intravascular pool per day. Distribution of the subclasses was such that the intravascular compartment contained 51-54% of the total body pools of G(1), G(2), and G(4), but 64% of the total body pool of G(3).The short survival and high fractional catabolic rate of G(3) is an inherent property of these molecules, and is not due to denaturation during isolation and radiolabeling. This was demonstrated by studies of a patient with a serum G(3)-myeloma protein. The survival of her own protein, separately labeled either in vivo with guanidoarginine-(14)C or in vitro with (125)I, was determined in the patient. Survivals of the in vivo and in vitro labeled proteins were identical.G(1) and G(3) serum concentrations and synthetic rates were determined. The mean serum concentration of G(1) was 6.8 mg/ml and that of G(3) was 0.7 mg/ml, while their synthetic rates were 25.4 and 3.4 mg/kg per day respectively. The low serum concentration of IgG(2) thus results from a combination of high catabolic and low synthetic rates. Studies in 10 patients with multiple myeloma showed that an elevated serum concentration of any IgG subclass was associated with shortened biologic half-life and increased fractional catabolic rate of all subclasses. The implications of this concentration-catabolism relationship are discussed. The serum concentration of nonmyeloma IgG was usually low in myeloma patients and the synthesis of nonmyeloma IgG was somewhat decreased, suggesting that low serum concentrations of nonmyeloma IgG result from decreased synthesis, as well as from an increased fractional catabolic rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative Determination of Serum Immunoglobulins in Antibody-Agar Plates
Fahey, J. L., & McKelvey, E. M. (1965) · The Journal of Immunology · doi:10.4049/jimmunol.94.1.84 · Cited by 1,528
Gamma-Globulin and Acquired Immunity to Human Malaria
COHEN, S., McGREGOR, I. A., & CARRINGTON, S. (1961) · Nature · doi:10.1038/192733a0 · Cited by 1,393
The Theory of Tracer Experiments with 131I-Labelled Plasma Proteins
Matthews, C. M. E. (1957) · Physics in Medicine & Biology · doi:10.1088/0031-9155/2/1/305 · Cited by 829
Waldmann, T. A., & Strober, W. (2015) · Chemical Immunology and Allergy · doi:10.1159/000385919 · Cited by 723
Self-citationA Theoretical Model of γ-Globulin Catabolism
BRAMBELL, F. W. R., HEMMINGS, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 449
Yount, W. J., Dorner, M. M., Kunkel, H. G., & Kabat, E. A. (1968) · The Journal of Experimental Medicine · doi:10.1084/jem.127.3.633 · Cited by 429
Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia
Fahey, J. L., Scoggins, R. B., Utz, J. P., & Szwed, C. F. (1963) · The American Journal of Medicine · doi:10.1016/0002-9343(63)90140-2 · Cited by 230
Metabolism of Human Gamma Macroglobulins*
Barth, W. F., Wochner, R. D., Waldmann, T. A., & Fahey, J. L. (1964) · Journal of Clinical Investigation · doi:10.1172/jci104987 · Cited by 199
Self-citationImmunoglobulins: Structural Studies of Immunoglobulin G
FRANGIONE, B., MILSTEIN, C., & PINK, J. R. L. (1969) · Nature · doi:10.1038/221145a0 · Cited by 176
FACTORS CONTROLLING SERUM γ-GLOBULIN CONCENTRATION
Fahey, J. L., & Robinson, A. G. (1963) · The Journal of Experimental Medicine · doi:10.1084/jem.118.5.845 · Cited by 173
Cited by
Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells
Bernasconi, N. L., Traggiai, E., & Lanzavecchia, A. (2002) · Science · doi:10.1126/science.1076071 · Cited by 1,304
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Waldmann, T. A., & Strober, W. (2015) · Chemical Immunology and Allergy · doi:10.1159/000385919 · Cited by 723
Self-citationREMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
Hale, G., Clark, M. R., Marcus, R., Winter, G., Dyer, M. J. S., Phillips, J. M., Riechmann, L., & Waldmann, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90588-0 · Cited by 688
B cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591
Antibody-based protection against HIV infection by vectored immunoprophylaxis
Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012) · Nature · doi:10.1038/nature10660 · Cited by 545
Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone Marrow
Halliley, J. L., Tipton, C. M., Liesveld, J., Rosenberg, A. F., Darce, J., Gregoretti, I. V., Popova, L., Kaminiski, D., Fucile, C. F., Albizua, I., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.016 · Cited by 545
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., & Khazaeli, M. B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4220 · Cited by 524
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Ordás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
Biological Activities of Immunoglobulins of Different Classes and Subclasses
Spiegelberg, H. L. (1974) · Advances in Immunology · doi:10.1016/s0065-2776(08)60254-0 · Cited by 496
Fc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Odendahl, M., Mei, H., Hoyer, B. F., Jacobi, A. M., Hansen, A., Muehlinghaus, G., Berek, C., Hiepe, F., Manz, R., Radbruch, A., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2507 · Cited by 424
St.Clair, E. W., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T., Kavanaugh, A., & Keystone, E. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10302 · Cited by 417
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
“In addition to Fc binding, the IgG subclass influences antibody catabolism rates, self-association and stability 349–352 , and changing the IgG subclass can affect antigen binding even when the variable regions are unchanged 182,348,353–368 .”
BackgroundIgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Yamamoto, K., Utsunomiya, A., Tobinai, K., Tsukasaki, K., Uike, N., Uozumi, K., Yamaguchi, K., Yamada, Y., Hanada, S., Tamura, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3575 · Cited by 354
Human Immunoglobulins: Classes, Subclasses, Genetic Variants, and Idiotypes
Natvig, J. B., & Kunkel, H. G. (1973) · Advances in Immunology · doi:10.1016/s0065-2776(08)60295-3 · Cited by 331
Firan, M., Bawdon, R., Radu, C., Ober, R. J., Eaken, D., Antohe, F., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.8.993 · Cited by 330
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G., & Roopenian, D. C. (2006) · International Immunology · doi:10.1093/intimm/dxl110 · Cited by 314
What is IgG4? A review of the biology of a unique immunoglobulin subtype
Nirula, A., Glaser, S. M., Kalled, S. L., & Taylora, F. R. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283412fd4 · Cited by 309
The therapeutic age of the neonatal Fc receptor
Pyzik, M., Kozicky, L. K., Gandhi, A. K., & Blumberg, R. S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00821-1 · Cited by 288
Stapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1608 · Cited by 286
“However the short half-life of one week for IgG3, compared with three weeks for the other subclasses, currently makes IgG1 the therapeutic subclass of choic”
BackgroundThe mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat
Jones, E. A., & Waldmann, T. A. (1972) · Journal of Clinical Investigation · doi:10.1172/jci107116 · Cited by 279
Self-citationAdvances in Human B Cell Phenotypic Profiling
Kaminski, D. A., Wei, C., Qian, Y., Rosenberg, A. F., & Sanz, I. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00302 · Cited by 272
The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199107113250201 · Cited by 253
McLachlan, S. M., & Rapoport, B. (2013) · Thyroid · doi:10.1089/thy.2012.0374 · Cited by 239
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Kiessling, P., Lledo-Garcia, R., Watanabe, S., Langdon, G., Tran, D., Bari, M., Christodoulou, L., Jones, E., Price, G., Smith, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan1208 · Cited by 211
Plasma cell survival in the absence of B cell memory
Hammarlund, E., Thomas, A., Amanna, I. J., Holden, L. A., Slayden, O. D., Park, B., Gao, L., & Slifka, M. K. (2017) · Nature Communications · doi:10.1038/s41467-017-01901-w · Cited by 210
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Maternal vaccination: moving the science forward
Faucette, A. N., Unger, B. L., Gonik, B., & Chen, K. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu041 · Cited by 81
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
Grevys, A., Frick, R., Mester, S., Flem-Karlsen, K., Nilsen, J., Foss, S., Sand, K. M. K., Emrich, T., Fischer, J. A. A., Greiff, V., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103746 · Cited by 51
“Humans have four IgG subclasses (IgG1–4), three of which have a serum half-life of roughly 3 weeks (IgG1,2,4), whereas it is 1 week for IgG3 (Morell et al., 1970).”
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.018 · Cited by 16
Metadata
- Authors
- Morell, A., Terry, W. D., & Waldmann, T. A.
- Venue
- Journal of Clinical Investigation
- Published
- 1970-04-01
- Volume
- 49
- Issue
- 4
- Pages
- 673-680
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2124467421
- Cited by
- 526
- References
- 16
- FWCI
- 24.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.